Improvements in the PSA screening process make it worth another look.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today reminded ...

Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States who have been diagnosed with prostate ...

Does prostate cancer run in families? Learn how affected relatives, inherited genes and age at diagnosis influence risk, and ...

The trial added 177Lu-PNT2002 to stereotactic body radiation therapy (SBRT) and found that median progression-free survival ...

Salvage radiation after surgery: If PSA rises after surgery, radiation to the area where the prostate was can still be ...

Choosing prostate cancer treatment takes more than explaining options. Explore strategies to communicate risks, clarify ...

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more ...

Prostate cancer is the second most common cause of death among men in the United States. A metro Atlanta non-profit is ...

Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysisSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: VCYT), ...

Scientists identified a driver of aggressive prostate cancer and a potential way to stop drug-resistant tumors forming.

As the new season of ‘Grey’s’ premieres, the actor opens up about facing cancer on screen and off ...